- Home
- Reports
- Pharmaceutical
- Circulating Tumor Cell Market
Circulating Tumor Cell (CTC) Market Share, Growth and Trends Analysis By Application (Research, Drug Development), Technology (CTC Enrichment, CTC Detection), End-User (Hospital & Clinics, Research & Academic Institutes, Diagnostic Centers) - Global Forecast Till 2023
ID: MRFR/Pharma/0854-CR | August 2018 | Region: Global | 110 pages
Circulating Tumor Cell Market Overview
In 2017, the global market size of circulating tumor cell (CTC) reached a valuation of USD 9,393.1 Mn. The market is projected to surpass a valuation of USD 28,300 Mn by the end of 2023, reflecting a healthy growth rate. The prevalence rate of CTC has gone up in recent years. The mechanism of CTC is responsible for a vast majority of deaths caused by cancer. Significant progress has been made in developing effective CTC diagnostics and treatment, though, survival rates remain moderate. Circulating tumor cells can be associated with different types of cancer prognosis including breast cancer, prostate cancer, and gastric cancer among others. Healthcare companies continue to focus on developing solutions that enable accurate and quick detection of CTC. The diagnosis and analysis of CTCs can help in early cancer detection and determine appropriate treatments tailored for specific cancer types.
Report Overview
This MRFR report offers a full-fledged analysis of the global market for circulating tumor cells. It also discuses the market opportunities for biomarkers active in the particular class as well as identifies the existing challenges. The primary objective of the report is to provide a five-year (2018-2023) revenue assessment of the global CTC market. MRFR’s report holds a fair perspective towards the CTC market and explores the application scope of the existing CTC technologies in clinical, research and drug development activities. The research document also profiled CTC technologies that are currently available, which include CTC Enrichment, CTC Detection and Combined Enrichment and Separation of CTC (CTC analysis). Revenue analysis on the basis of major end users of CTC technology covers hospital & clinics, research & academic institutes and diagnostic centers. The report undertakes a market study on a global level, which covers South America, North America, Asia Pacific (APAC), the Middle East & Africa (MEA) and Europe.
Report Coverage
Value, Market Share, Player Analysis, value chain analysis, Porter's five forces model, demand & supply: gap analysis, investment opportunities analysis, pricing analysis, technological trends, country level break down for services segment.
Circulating Tumor Market Companies Profiled
Ikonisys Inc., Greiner Bio-One International GmbH, Thermo Fisher Scientific, SRI International, STEMCELL Technologies, Miltenyi Biotec, Menarini Silicon Biosystems, QIAGEN Hannover (QIAGEN), F. Hoffmann-La Roche Ltd, NanoString Technologies, Inc, Fluxion Biosciences, Inc., GE Healthcare, ApoCell, Advanced Cell Diagnostics, Inc. (Bio-Techne Corporation), Epic Lifesciences, Celltraffix Inc.
Research Methodology
Market Research Future (MRFR) leverages its vast repository of market data along with fail-safe statistical tools for delivering accurate foresight. Market outcomes are derived through extensive primary research. Primary data collected is verified by secondary research from credible sources such as SEC filings, whitepaper references, paid database services, annual reports, and research publication by national and international organizations among others. Robust analytical algorithms are employed for mapping data and drawing impactful insight into the market. Top-down and bottom-up approaches are engaged for accurate estimation of the market size and revenue. A multi-layer verification process evaluated the data points offered in our reports. The aim is to deliver an actionable intelligence supported by graphical representations for enhanced lucidity.
Other Description
- Market Denomination- USD
- Base year- 2017
- Forecast Period- From 2018 to 2023
For the scope of the research, MRFR’s report offers a comprehensive segmental analysis of the global market for circulating tumor cell
By Application
- Clinical
- Research
- Drug Development
By Technology
- CTC Enrichment
- CTC Detection
- Combined Enrichment and Separation of CTC (CTC analysis)
By End-User
- Hospital & Clinics
- Research & Academic Institutes
- Diagnostic Centers
BY Region
- Americas
- North America
- S
- Canada
- South America
- Europe
- Western Europe
- Germany
- K
- France
- Spain
- Italy
- Rest of Western Europe
- Eastern Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- Republic of Korea
- Rest of Asia Pacific
- Middle East & Africa
- Middle East
- Africa
Intended Audience
- Hospitals and clinics
- Research institutes
- Pharmaceutical & Bioterchnology Industries
- Suppliers and distributors
- Potential investors
- Raw material suppliers
- Government Associations
Frequently Asked Questions (FAQ) :
Global Circulating Tumor Cell Market is expected to touch a valuation of USD 28,300 million by 2023.
Global Circulating Tumor Cell Market stood at USD 9,393.1 million in 2017.
Global Circulating Tumor Cell Market can expand at a CAGR of 20.32% from 2018 to 2023.
Hospitals & clinics are predicted to be the biggest end-use segment of the Global Circulating Tumor Cell Market.
Americas can dominate the Global Circulating Tumor Cell Market.
ApoCell, F. Hoffmann-La Roche Ltd, Celltraffix Inc., QIAGEN Hannover (QIAGEN), STEMCELL Technologies, Thermo Fisher Scientific, Greiner Bio-One International GmbH, SRI International, GE Healthcare, Ikonisys Inc., NanoString Technologies, Inc, Fluxion Biosciences, Inc., Miltenyi Biotec, Menarini Silicon Biosystems, Advanced Cell Diagnostics, Inc. (Bio-Techne Corporation), and Epic Lifesciences are the major players of the Global Circulating Tumor Cell Market.
The global circulating tumor cell market was valued at USD 9393.1 Million in 2017 and is expected to attain USD 28,399.2 Million by the end of 2023. Factors such as growing prevalence of cancer, increasing research and development activities, advances in biomedical and bioengineering technology and rise in global geriatric population are factors which will shape the global circulating tumor cell market and help it attain a CAGR of 20.32% over the forecast period of 2018-2023.
Circulating tumor cells find their application in cancer diagnostics and management and growing incidences of oncology diseases boost the growth of the global circulatory tumor cells market. CTCs are used as a biomarker for early detection of cancer; they act as an indicator of treatment response and are beneficial in predicting outcomes and prognostication in cancer management.
Persistent need for treatment of various chronic diseases prompts vast investments by the pharmaceutical and biotechnology sector on research and development to develop breakthrough therapies for cancer and other chronic illnesses which is fostering the growth of the global circulating tumor cells market.
CTC tests are expensive as they combine a number of enrichment and detection steps which require various systems, assays, instruments and test kits that hinder the growth of the market.
Huge unmet medical needs in developing regions and a severe lack of proper medical facilities in weak economies challenge the growth of the market, however developing economies offer a high potential for growth opportunities for the global circulatory tumor cell market as it provides room for market growth in the untapped regions. Vendors can achieve growth by marking their presence in such regions by addressing the healthcare challenges.
The global circulatory tumor cells market has been segmented based on application, technology, and end-user. By application, the market has been segmented into clinical, research, drug development, and others. The clinical segment is the largest segment and accounts for 63% of the share. The clinical segment is further segmented into clinical prognostic, diagnosis and management of tumor malignancies, and drug decision. The clinical segment was valued at USD 5,920.9 million in 2017 and is expected to reach USD 18,225.8 million by the end of 2023. The drug development segment is expected to exhibit sturdy growth over the forecast period as pharmaceutical and biotech companies are increasingly focusing on CTC for drug development.
By technology, the market has been segmented into CTC enrichment, CTC detection, and CTC analysis. Technology-wise, CTC enrichment is the largest segment owing to its effectiveness in reduction of time needed for isolation of rare CTCs.
By end-user, the market has been segmented into hospitals and clinics, research and academic institutes, diagnostic centers, and others. Hospitals and clinics segment dominates the global market and is expected to attain USD 9,184.9 million by the end of 2023. There has been an incessant need for diagnosis and treatment of cancer which will help the hospitals and clinics segment grow at an impressive CAGR of 20.92% over the forecast period.
Regional Analysis
The global circulatory tumor cell market spans across the regions of the Americas, Europe, Asia Pacific and the Middle East & Africa. Globally, the Americas account for the largest share of the circulating tumor cell market owing to the high prevalence of cancer in the region. Moreover, the Americas have a robust healthcare sector and is an early adopter of new technologies for healthcare purposes which drives the market in the region. The America market for circulating tumor cell is expected to reach USD 13,011.5 Million by the end of 2023 and expand at a CAGR of 20.56% over the forecast period.
Europe is the second largest market for circulating tumor cells and is closely followed by Asia Pacific. Asia Pacific market is mushrooming in size and is expected to expand at a CAGR of 20.84% over the forecast period. The untapped markets of Asia Pacific store high growth opportunities for the global market. Rising incidences of cancer along with technological advancements favor the growth of the market in the region.
Competitive Tracking
The global circulating tumor cells market is a highly competitive one with the presence of a multitude of local as well as regional players. The market players are pouring in money for R&D and are competing based on cost, quality, and reliability. The notable players in the global circulating tumor cell market include Greiner Bio-One International GmbH, Thermo Fisher Scientific, STEMCELL Technologies, Menarini Silicon Biosystems, F. Hoffmann-La Roche Ltd, Fluxion Biosciences, Inc., Ikonisys Inc., SRI International, Miltenyi Biotec, QIAGEN Hannover (QIAGEN), and NanoString Technologies, Inc.
TABLE OF CONTENT
Global Circulating Tumor Cells Market: Competitive Landscape
The global circulating tumor cells market is characterized by the presence of many global, regional, and local vendors. The market is highly competitive with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront the market growth. The vendors compete based on cost, quality, and reliability. It is decisive for the vendors to provide cost-efficient and high-quality products, to survive and succeed in an intensely competitive market environment.
The growth of the market players is dependent on market conditions, government support, and industry development. Thus, major players should focus on expanding geographically and improving their products. They primarily focus on the development of novel products. Although international players are dominating the market, regional players with small market shares also have a presence. International players are likely to strengthen their presence worldwide through acquisitions during the forecast period. It has also been estimated that improvement of the global economic scenario combined with efforts to enhance the infrastructure in emerging nations, is fueling the market growth, thereby making it an ideal time for new products and increase the global market share.
Players with better technical and financial resources can develop innovative products. Therefore, vendors must develop new technologies and stay abreast of emerging technologies that could affect the continuing competitiveness of their treatment lines in the market.
- Hoffmann-La Roche Ltd has a vast product portfolio in the circulating tumor cells industry. The company also has a wide geographic presence as it operates in various countries across the world. It has a significant presence in North America, Europe, and the Middle East and Africa, with commercial, manufacturing, and research facilities in more than one dozen countries.
